Boundless Bio to merge with Serapha all-stock deal, $230 m concurrent private placement
Boundless Bio to merge with Serapha Bio in all-stock deal, alongside $230 million concurrent private placement
- Transaction includes an expected $44–48 million pre-closing cash dividend payable to Boundless Bio stockholders
- Following closing, Boundless Bio stockholders will own about 3.7% of the combined company, to be renamed Serapha Bio
- Serapha Bio is a privately held company entering a definitive all-stock merger agreement with Boundless Bio
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.